Abstract 205P
Background
Most current pre-clinical models lack reliability in predicting effects of immunotherapeutic drugs intended for treatment of advanced cancer diseases. The key problem is that they don’t reflect the complexity of the tumor microenvironment. Patient-derived tumor models, like precision cut tissue slices, present an opportunity to test the effect of drugs on both tumor cells and cells in the tumor microenvironment.
Methods
We have established an ex vivo bladder tumor model using Precision Cut Bladder Tumor Slices (PCTS). PCTS maintain the original cellular composition and tissue architecture, making them conducive to the testing of various therapies. Upon treatment with immunogenic agents, cytostatic drugs, and therapeutic antibodies, response signatures were analyzed using H&E staining, high-plex flow cytometry, and multiplex immunoassay (Luminex) of secreted cyto- and chemokines. Slices were generated with a vibratome and cultivated for two days to ensure stable tissue viability.
Results
Cellular composition and treatment responses were evaluated based on expression of tumor markers (EpCam and Nectin-4), presence of immune cells (e.g. CD45, CD3, CD19, CD11c), and activation markers (e.g. CD137, CD69). Spatial information was obtained with H&E stainings enabling insights into structural changes. Analysis of supernatants revealed dose-dependent changes in secretion of relevant cytokines and chemokines like Granzyme B, CXCL10, and MIP3a. Additionally, the results clearly reflect patient heterogeneity.
Conclusions
The PCTS model represents a promising approach to 1.) evaluate the efficacy of novel drug candidates on cells in the tumor microenvironment and 2.) screen different treatments and their combinations to achieve the best possible therapy response.
Legal entity responsible for the study
The authors.
Funding
Co-funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under grant agreement 847583, Cancera Foundation, Mats Paulsson Foundation, Inga-Britt och Arne Lundbergs Forskningsstiftelse, The Royal Physiographic Society in Lund, John och Augusta Perssons Stiftelse, Stiftelse Tornspiran, and Crafoord Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract